Member Info for woody2002

Pretty sure there was an RNS explaining this will onky be released into the UK market for now.

You said about 10 days ago you felt sorry for new buyers and that this was going below 1.5p. Why the big change of heart. Youve been a doomonger for as long as I can rememeber. Ill know not to take anything you say too seriously going forward. All positive posts this week....?

Cant help but notice ur change of sentiment recently Russell.

Someone id buying or they're playing with the spread as its judt changed > 8%

I cant buy £600 worth.

Apple I don't believe Goldbloc will be released into the Indian market in 2018. its UK only unless I'm mistaken

uninformed attention seeker with nothing of substance to share. thanks for trying though!

They seem to be looking for shares mate. Let them lift the bid if they eant them! :)

Advisory board consisting of members of the patient advocate, hospital and consultant community, all with specialisms in oncology and particularly in end-of-life care in cancer patients was convened to DISCUSS the RESULTS and impact of VAL401.  The meeting was organised and executed by the independent communications company, Hayward Medical, who provided a report detailing the ideas and enthusiasm the participants showed for the development of VAL401 to date.  In particular the need for a treatment that can be used to ALLEVIATE symptoms even in END-stage patients was highlighted and that the CO-PRESCRIPTION of a drug to provide supportive benefits in ADDITION to anti-cancer benefits would be valuable from the beginning of the patient journey, ALONGSIDE currently used approaches. The participants' individual comments included that they would be confident taking VAL401 IMMEDIATELY on cancer diagnosis, alongside standard of care treatment; that every month of additional life secured is PRICELESS, particularly with maintained quality, and in fact that, terminal patients often prefer to retain their Quality of Life than to risk further disruptive treatments!!!!!!!!!

Good evening all, just got in and had a quick overview of the results. This is always horrible as your put in the precarious position of discussing deaths but this is what I read: I would like to clarify OS and PFS as some people are using the work "extended", I made this mistake when understanding it but the results can't be extended values as they aren't being compared to standard of care. The values given for both are from a set point in time " TIME OF SCREENING". So the data being presented is at it looks, for PFS it was "7.2 weeks", for OS it was "10.9". The data also shows importantly that the per protocol group leader was "15.3 weeks" with the minimum "6.9 weeks". For the intention to treat, unfortunately one died within 0.4 weeks and the second one who completed less than 10 days you cannot identify his data singly. he would of been at the minimum for PFS (due to withdrawal) but for OS or he could of been in the higher percentile, thats data you can't pull out. BUTTTT we can divulge the rest of the data against expectations. As several have said this was never going to be pretty as a dataset as these were extremely sick people who were within a days/weeks of death (apologies if this causes offence but people are under the illusion this trial was for just normal stage IV lung cancer). From the offset it was ALWAYS about the search for quality of life with POSSIBLE efficacy.  If you thought different and have been invested in this share, then this is your fault for not realising what this drug is and its intentions. The dataset by improvement of core quality of life is a resounding success, apart from irritability the balance is very much in 401's favour. The Cmax scores doesn't highlight any irregularities. NOW the question is what does this mean for patients and the company. Well I don't have access to normal/placebo dataset so is "15.3" amazing?? is PFS of "11.6 weeks" impressive? its now upto professionals embedded in Pharma companies to decide whether this data alone is substantial enough to warrant a JV or commercial deal, only they can answer that question. If anyone knows a medical professional in Oncology then now is the time to ask, but based of the reports stated by other below regards the "advisory board" comment in June RNS then its SEEMS to be exciting and on paper better than expected/standard.......repost of FLT2017s comments yesterday. Dont expect the trolls to read it but Its better than I could have put it!

Well if its on Twitter it must be true! Im selling up thats it lol. Lot of nonsense again...

Folks I dont want to burst anyones bubble or suggest the appointment is irrelevant but......... Lionsgold, the gold-focused exploration company with assets in India and Finland, and a financial technology ("fintech") subsidiary that provides online accounts for holding physical gold, is pleased to announce that Mr. Alan Davies has agreed to become Global Strategy Consultant for Lionsgold.  Mr. Davies is the former Chief Executive of Energy & Minerals at Rio Tinto PLC ("Rio Tinto").  He has more than twenty years' experience in operational and strategic development in the global mining industry, including having been Chief Executive of Diamonds & Minerals at Rio Tinto, and CFO of Rio Tinto Iron Ore.  Mr. Davies is deeply experienced in India, having had executive responsibility for Rio Tinto in India for approximately eight years, and over ten years of direct project responsibility in India.   Different companies etc but having a former RIO exec. As advisor doesnt mean too much.

Although, along with the submission of the Clinical Study Report to the Ministry of Health in Tbilisi, this concludes our formal obligations on trial reporting, we are also in the process of publication through peer-reviewed industry journals, which will provide interpretation of these listed results. I look forward to announcing the release of these further publications in due course."....... From today, looking forward to these being reviewed by professionals.

Great post!

Bought In with just under 130k shares today. Hopefully this is the floor...GLA

Why are people discussing things we already knew? We've known for ages there was only 8 people in this trial. All these people spend every day in life blasting the BOD and the company as a whole and you dont even keep up to date with the companies most advanced pivotal CT. Since these results we've had several updates on discussions and also the______________ Advisory board of UK Key Opinion Leaders ("Advisory Board") An Advisory board consisting of members of the patient advocate, hospital and consultant community, all with specialisms in oncology and particularly in end-of-life care in cancer patients was convened to discuss the results and impact of VAL401.  The meeting was organised and executed by the independent communications company, Hayward Medical, who provided a report detailing the ideas and enthusiasm the participants showed for the development of VAL401 to date.  In particular the need for a treatment that can be used to alleviate symptoms even in end-stage patients was highlighted and that the co-prescription of a drug to provide supportive benefits in addition to anti-cancer benefits would be valuable from the beginning of the patient journey, alongside currently used approaches. The participants' individual comments included that they would be confident taking VAL401 immediately on cancer diagnosis, alongside standard of care treatment; that every month of additional life secured is priceless, particularly with maintained quality, and in fact that, terminal patients often prefer to retain their Quality of Life than to risk further disruptive treatments.   2018 BIO International Convention Dr Dilly attended the BIO International Convention in Boston during the week of 4 June 2018.  Recognised as the largest partnering and exhibition event in the industry, BIO is an opportunity to access global biotech and pharma companies.  Presenting the VAL401 project, Dr Dilly held meetings to progress commercial conversations further with current and future partners, as well as presenting the project to new audiences.   Notification of Acceptance re Second New Zealand patent ValiSeek has received notification that a further method-of-treatment patent has been allowed by the New Zealand Patent Office covering the use of VAL401 in the treatment of pancreatic adenocarcinoma.   Dr Suzy Dilly, CEO of ValiSeek, commented: "The external validation from both the Advisory Board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market.  These developments are a valuable addition to our licensing package, clarifying the final stages of clinical testing towards commercial use."  

Malcy made a few comments a while back and was bullish on Rose.

Bp82 - I dont rememeber then saying Q1 tbh. They've just said next year unless im mistaken?

The trial participants had exhausted all options and were all but dead. This was the nature of the trial unfortunately. The fact there was deaths and complications shouldnt be a surprise. Unless im mistaken the results are old they've just received approval to be published. Nothing has changed...

Thats gonna get the BB talking...